Figure 2From: Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger’s disorder: a 12-week prospective, open-label study Changes in mean ABC scores. ABC, Aberrant Behavior checklist.Back to article page